Search Results

You are looking at 1 - 10 of 51 items for :

  • "anticoagulation" x
Clear All
Full access

John Fanikos and Samuel Z. Goldhaber

treatment in patients with cancer and thrombosis . Blood 2002 ; 100 : 3484 – 3488 . 13. Paraleti G Legnani C Lee A . A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients

Full access

Jeffrey A. Kline and David W. Miller

mechanisms have been proposed for the hypercoagulability that causes patients to be refractory to standard anticoagulation. 26 One enduring theory implicates the paraneoplastic release of tissue factor, which activates the extrinsic clotting pathway. The

Full access

Michael L. Linenberger

extremity deep venous thrombosis . Cardiovasc Intervent Radiol 2002 ; 25 : 524 – 526 . 117. Sabeti S Schillinger M Mlekusch W . Treatment of subclavian-axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis

Full access

Michael B. Streiff

-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism . N Engl J Med 2003 ; 349 : 631 – 639 . 16. Bona RD Hickey AD Wallace DM . Efficacy and safety of oral anticoagulation in patients with cancer . Thromb Haemost

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. Smith, Gary C. Yee and Anaadriana Zakarija

pharmacologic anticoagulation measures based on both the perceived risk of bleeding (i.e., contraindications to anticoagulation) and the cancer status of the patient. These NCCN Guidelines define VTE broadly to include deep venous thrombosis (DVT), pulmonary

Full access

Anita Pudusseri and Alex C. Spyropoulos

-established association with venous thromboembolism (VTE), places these patients at risk for perioperative thromboembolism. 3 It is also well-established that continuing patients on oral anticoagulation therapy during the periprocedural period is associated with an

Full access

Andrew S. Epstein and Eileen M. O'Reilly

Cochrane) involving the key words (and associated subterms) pancreas cancer, anticoagulation , and thrombosis . From a search yield of 1895 results, articles chosen for inclusion herein predominantly consisted of original studies on preclinical

Full access

Cocav A. Engman and Leo R. Zacharski

Clin Oncol 2000 ; 18 : 3078 – 3083 . 12. Palareti G Legnani C Lee A . A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy . Thromb

Full access

Todd M. Getzen and John E. Rectenwald

of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? J Vasc Surg 1998 ; 28 : 800 – 807 . 26. Krauth D Holden A Knapic N . Safety and efficacy of long-term oral anticoagulation in

Full access

Paul C. Hendrie and David A. Garcia

Better strategies to treat and prevent VTE in patients with cancer are needed. Until recently, anticoagulation for the prevention and treatment of VTE has been limited to oral vitamin K antagonists (eg, warfarin) and parenteral agents derived from